课题基金 / 基金详情

A Novel Platform to Identify and Treat Transitional Age Youth With Alcohol Use Disorder

A Novel Platform to Identify and Treat Transitional Age Youth With Alcohol Use Disorder
识别和治疗患有酒精使用障碍的过渡年龄青少年的新平台
批准号:
10761094
负责人:
Renee Garett
金额:
$27.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-15 至 2024-07-31

项目摘要

项目成果

Renee Garett的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 本建议旨在确定建立数据管理系统的可行性和可接受性 为研究人员和卫生部门量身定制的平台,试图识别年轻人饮酒 使用障碍(AUD)谁没有在4年制大学注册。这是一个迫切需要研究的领域; 滥用高峰在年轻人中。由于方便,大多数参与者样本都涉及年轻人 就读于四年制大学。迫切需要研究来识别患有AUD的年轻人, 参加4年制大学,为他们提供潜在的干预措施,减少这种健康不平等。 research. Facebook和谷歌等顶级科技公司已经成为开发DMP的专家, 将与产品相关的消费者作为目标,这些消费者在统计上可能点击广告并购买产品。 产品例如,制药公司可以使用符合HIPAA的身份验证来识别移动的设备 由统计上可能患有抑郁症的个人拥有(即,“看起来相似的受众定位), 各种健康(例如,药房索赔),数字行为(例如,访问的网站)和人口统计数据集, 帮助精确地改进何时、如何以及提供什么类型的抑郁症药物或相关广告 以增加患者的兴趣。然而,据我们所知,没有任何证据可以用来帮助 识别患有AUD的个人,以增加他们在研究中的入组人数。这意味着卫生部门和 试图识别和招募患有AUD的年轻人的研究人员需要亲自招募(这是 耗时且缺乏可扩展性)或通过使用Facebook和其他广泛的传统DMP, 是低效的并且不是定制的(即,它浪费时间和金钱支付广告,将显示给许多人, 没有OUD)。我们寻求创造(并评估可行性和可接受性)的第一个量身定制的 研究人员和卫生部门试图识别未参加4- 年大学。通过合作伙伴关系和初步研究,我们已经开发出与行业广告 在COVID-19大流行期间,我们将利用我们团队的经验和数据, NIDA资助的SBIRs帮助物质使用研究人员,NIDA资助的R34表明患者 会认为这种做法是可以接受的。在第1阶段应用之后,这种方法可能会在以后扩展(以及 定制的几乎所有的临床条件)是第一个已知的增加参与者的登记, 健康相关的研究。
英文摘要
Project Summary This proposal seeks to determine the feasibility and acceptability of developing a data management platform (DMP) tailored for researchers and health departments attempting to identify young adults with alcohol use disorder (AUD) who are not enrolled in 4-year colleges. This is an urgent area of research; rates of alcohol misuse peak among young adults. Due to convenience, most participant samples have involved young adults enrolled in 4-year colleges. Research is urgently needed to identify young adults with AUD who are not enrolled in 4-year colleges to provide them with potential interventions and reduce the health inequity of this research. Top technology companies, such as Facebook and Google, have become experts at developing DMPs that target consumers relevant to a product who are statistically likely to click on advertisements and purchase the product. For example, pharmaceutical companies can use a HIPAA-compliant DMP to identify mobile devices owned by individuals statistically likely to have depression (i.e., “look-alike audience targeting) by referencing a variety of health (e.g., pharmacy claims), digital behavior (e.g, websites visited) and demographic datasets to help improve precisely when, how, and what type of depression medication or related advertisement to deliver to each device to increase patient interest. However, to our knowledge, no DMP exists that can be used to help identify individuals with AUD to increase their enrollment in research. This means that health departments and researchers attempting to identify and enroll young adults with AUD need to either recruit in person (which is time-consuming and lacks scalability) or through the use of Facebook and other broad traditional DMPs, which is inefficient and not tailored (i.e., it wastes time and money paying for ads that will be shown to many people without OUD). We seek to create (and evaluate the feasibility and acceptability of) the first DMP tailored for researchers and health departments attempting to identify young adults with AUD who are not enrolled in 4- year colleges. Through partnerships and preliminary research we have developed with industry advertising partners during the COVID-19 pandemic, we will leverage our team’s experience and data from previous NIDA-funded SBIRs to help substance use researchers, and a NIDA-funded R34 suggesting that patients would find this approach acceptable. Beyond this Phase 1 application, this approach might later be scaled (and tailored to almost all clinical conditions) to be the first known DMP for increasing enrollment of participants to health-related research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Opioid Support and Risk Reduction Online Platform
  • 批准号:
    10013077
  • 项目类别:
  • 资助金额:
    $23.9万
  • 财政年份:
    2021
  • 负责人:
    Renee Garett
  • 依托单位:
海外基金